Header Logo

Connection

ROBERT ATMAR to Middle Aged

Back to Details
This is a "connection" page, showing publications ROBERT ATMAR has written about Middle Aged.
ROBERT ATMAR
Connection Strength
1.012
Middle Aged
  1. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.059
  2. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.056
  3. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.048
  4. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020 08 21; 69(8):1-24.
    View in: PubMed
    Score: 0.044
  5. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.042
  6. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.041
  7. Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. J Infect Dis. 2019 07 19; 220(4):603-614.
    View in: PubMed
    Score: 0.040
  8. An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. J Infect Dis. 2019 01 09; 219(3):410-414.
    View in: PubMed
    Score: 0.039
  9. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial. J Infect Dis. 2016 Sep 15; 214(6):845-53.
    View in: PubMed
    Score: 0.033
  10. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.030
  11. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis. 2014 Apr 01; 209(7):1016-22.
    View in: PubMed
    Score: 0.027
  12. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.024
  13. Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
    View in: PubMed
    Score: 0.024
  14. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
    View in: PubMed
    Score: 0.023
  15. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
    View in: PubMed
    Score: 0.022
  16. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010 Oct 15; 202(8):1212-8.
    View in: PubMed
    Score: 0.022
  17. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008 Oct; 14(10):1553-7.
    View in: PubMed
    Score: 0.019
  18. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol. 2008 Jan; 46(1):198-205.
    View in: PubMed
    Score: 0.018
  19. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
    View in: PubMed
    Score: 0.017
  20. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005 May; 50(4):322-30.
    View in: PubMed
    Score: 0.015
  21. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
    View in: PubMed
    Score: 0.015
  22. Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
    View in: PubMed
    Score: 0.015
  23. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 Feb 15; 47:126702.
    View in: PubMed
    Score: 0.015
  24. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 Feb 15; 47:126689.
    View in: PubMed
    Score: 0.015
  25. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.014
  26. Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care. J Antimicrob Chemother. 2024 03 01; 79(3):559-563.
    View in: PubMed
    Score: 0.014
  27. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
    View in: PubMed
    Score: 0.012
  28. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
    View in: PubMed
    Score: 0.012
  29. 'String Test' for Hypermucoviscous Klebsiella pneumoniae. Am J Med. 2021 10; 134(10):e520-e521.
    View in: PubMed
    Score: 0.011
  30. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
    View in: PubMed
    Score: 0.011
  31. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 11 05; 383(19):1813-1826.
    View in: PubMed
    Score: 0.011
  32. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Jul; 162(1):167-73.
    View in: PubMed
    Score: 0.011
  33. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019 12 13; 68(4):1-14.
    View in: PubMed
    Score: 0.010
  34. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019 07 19; 68(2):1-33.
    View in: PubMed
    Score: 0.010
  35. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.010
  36. Dialysis Catheter-related Bloodstream Infections in Patients Receiving Hemodialysis on an Emergency-only Basis: A Retrospective Cohort Analysis. Clin Infect Dis. 2019 03 05; 68(6):1011-1016.
    View in: PubMed
    Score: 0.010
  37. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
    View in: PubMed
    Score: 0.009
  38. Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. J Virol. 2017 07 15; 91(14).
    View in: PubMed
    Score: 0.009
  39. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
    View in: PubMed
    Score: 0.008
  40. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
    View in: PubMed
    Score: 0.008
  41. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.008
  42. Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections--A Prospective Cohort Study. PLoS Pathog. 2015 Jun; 11(6):e1004869.
    View in: PubMed
    Score: 0.008
  43. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine. 2015 Jan 15; 33(4):568-76.
    View in: PubMed
    Score: 0.007
  44. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.007
  45. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15; 211(6):870-8.
    View in: PubMed
    Score: 0.007
  46. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014 Dec 01; 210(11):1763-71.
    View in: PubMed
    Score: 0.007
  47. Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. BMC Infect Dis. 2013 Jun 19; 13:276.
    View in: PubMed
    Score: 0.007
  48. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013 Mar 15; 207(6):974-81.
    View in: PubMed
    Score: 0.006
  49. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.006
  50. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. mBio. 2012; 3(4):e00159-12.
    View in: PubMed
    Score: 0.006
  51. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1991 Jan 15; 114(2):119-27.
    View in: PubMed
    Score: 0.006
  52. Characterization of norovirus-associated traveler's diarrhea. Clin Infect Dis. 2010 Jul 15; 51(2):123-30.
    View in: PubMed
    Score: 0.005
  53. Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2010 Jun; 125(6):1369-1378.e2.
    View in: PubMed
    Score: 0.005
  54. Comprehensive analysis of a norovirus-associated gastroenteritis outbreak, from the environment to the consumer. J Clin Microbiol. 2010 Mar; 48(3):915-20.
    View in: PubMed
    Score: 0.005
  55. Aichi virus, norovirus, astrovirus, enterovirus, and rotavirus involved in clinical cases from a French oyster-related gastroenteritis outbreak. J Clin Microbiol. 2008 Dec; 46(12):4011-7.
    View in: PubMed
    Score: 0.005
  56. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis. 2008 Jan 15; 8:4.
    View in: PubMed
    Score: 0.005
  57. Inactivated influenza vaccination for people with spinal cord injury. Arch Phys Med Rehabil. 2004 Nov; 85(11):1886-9.
    View in: PubMed
    Score: 0.004
  58. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
    View in: PubMed
    Score: 0.003
  59. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Oct 15; 168(8):968-75.
    View in: PubMed
    Score: 0.003
  60. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol. 2003 Jun 10; 37(1):69-75.
    View in: PubMed
    Score: 0.003
  61. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002 May; 81(3):213-27.
    View in: PubMed
    Score: 0.003
  62. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med. 2001 Dec 01; 164(11):2114-9.
    View in: PubMed
    Score: 0.003
  63. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
    View in: PubMed
    Score: 0.003
  64. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 Oct 28; 341(18):1336-43.
    View in: PubMed
    Score: 0.003
  65. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 1999 Oct 14; 18(5-6):531-9.
    View in: PubMed
    Score: 0.003
  66. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis. 1998 Nov; 27(5):1231-7.
    View in: PubMed
    Score: 0.002
  67. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998 Jun; 26(6):1418-24.
    View in: PubMed
    Score: 0.002
  68. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997 Aug; 25(2):230-9.
    View in: PubMed
    Score: 0.002
  69. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis. 1992 Feb; 14(2):403-11.
    View in: PubMed
    Score: 0.002
  70. B-cell activation and differentiation by HIV-1 antigens among volunteers vaccinated with VaxSyn HIV-1. J Acquir Immune Defic Syndr (1988). 1992; 5(7):719-25.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.